Abstracts Archive - Page 291 of 2607 - ACR Meeting Abstracts

Abstract Number: 1561 • ACR Convergence 2024
Association of Large Vessel Vasculitis and Development of SSc and SSc-Associated Antibodies: Impact of Pulmonary Arterial Hypertension
Brett Dinner¹, Ahmed Abdelmaksoud², Ann Igoe³, Taylor Viggiano⁴ and Vivek Nagaraja⁵, ¹Creighton University, Paradise Valley, AZ, ²University of California, Riverside, Riverside, CA, ³Flow, Tempe, AZ, ⁴Mayo Clinic, Phoenix, ⁵Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Large vessel vasculitis (LVV) comprises a spectrum of rare, potentially life-threatening disorders, including giant cell arteritis (GCA) and Takayasu's arteritis (TAK), defined by granulomatous…
Abstract Number: 1544 • ACR Convergence 2024
Comparison of Efficacy and Safety Between Belimumab and Telitacicept in the Treatment of Systemic Lupus Erythematosus
wanling wei, ling lei, Cheng Zhao, hanyou mo, zhanrui chen, leting zheng, jing wen, Fang Qin, xiaoling liao, wen zeng and fei dong, The First Affiliated Hospital of Guangxi Medical University, nanning, China (People's Republic)
Background/Purpose: B cells play an important role in the pathogenesis of systemic lupus erythematosus(SLE).Multiple biological agents with B lymphocyte as the therapeutic target have recently emerged…
Abstract Number: 1557 • ACR Convergence 2024
Estimation of Cardiovascular Risk in Patients with Systemic Sclerosis – Accuracy of Tools Based on SCORE and Its Modifications Compared to Ultrasound Examination of Subclinical Atherosclerosis
Sabína Oreská¹, Aneta Prokopcová², Hana Storkanova¹, Jaroslav Kudlicka³, Vladimir Tuka⁴, Ondrej Mikes⁴, Zdislava Krupickova⁴, Martin Satny⁴, Eva Chytilova⁴, Jan Kvasnicka⁴, Maja Spiritovic⁵, Barbora Hermankova⁶, Petr Cesak⁷, Marian Rybar⁸, Karel Pavelka⁹, Ladislav Šenolt², Radim Becvar¹, Jiří Vencovský², Michal Vrablik⁴ and Michal Tomcik¹, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴3rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, ⁵Institute of Rheumatology, Prague, Czech Republic, Prague, ⁶Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ⁷Department of Human Movement Laboratory, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, ⁸Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, Kladno, Czech Republic, Kladno, ⁹Institute of Rheumatology and Charles University, Praha, Czech Republic
Background/Purpose: Patients with systemic sclerosis (SSc) have increased cardiovascular (CV) risk due to accelerated atherosclerosis (ATS) caused by systemic inflammation, and vascular impairment. To date,…
Abstract Number: 0439 • ACR Convergence 2024
Contraception Counseling and Contraception Use Among SLE and RA/JIA Patients at a Public Medical Center in Los Angeles: Investigating Teratogenic Medication Use and Language Preferences
Laura Kobashigawa¹, Cassidy Hernandez-Tamayo², Katherine Ruddy³, Melissa Wilson² and Leanna Wise⁴, ¹University of Southern California/Los Angeles General Medical Center, Pasadena, CA, ²Keck School of Medicine of USC, Los Angeles, CA, ³University of Southern California/ Los Angeles General Medical Center, Los Angeles, CA, ⁴LAC+USC/Keck Medicine of USC, Pasadena, CA
Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)/juvenile idiopathic arthritis (JIA) frequently impact women of reproductive age. Management of these patients is particularly important…
Abstract Number: 1049 • ACR Convergence 2024
Very Low Uptake of Biosimilar Adalimumab in the First 9 Months of Availability in Rheumatology
Eric Roberts¹, Gabriela Schmajuk² and Jinoos Yazdany³, ¹University of California, San Francisco, SF, CA, ²UCSF / SFVA, San Francisco, CA, ³UCSF, San Francisco, CA
Background/Purpose: In 2021, over 300,000 patients in the United States used adalimumab, making it one of the highest-grossing drugs globally. In 2023, patent exclusivity for…
Abstract Number: 1308 • ACR Convergence 2024
Measuring the Educational Impact of a Collaboration Between RheumMadness and TheMednet
Nina Couette¹, Herveen Kaur Singh², Nadine Housri³, Eric Wilson⁴, Benjamin Lueck⁵, Sabahat Usmani⁶, Laura Arneson⁷, Meredith Balbach⁸, Lauren Phillips⁹, John Kellogg⁵, Courtney Bair¹⁰, Michael Macklin¹¹, Iman Qaiser¹², Amanda Rodriguez¹³, Akrithi Garren¹⁴, Matthew Sparks¹⁵, Lisa Criscione-Schreiber⁵, Guy Katz¹⁶, David Leverenz¹⁵ and Melissa Briones¹⁷, ¹Genesis Healthcare System, Columbus, OH, ²theMednet, New York, NY, ³Yale School of Medicine, New Haven, CT, ⁴Duke University Hospital, Durham, NC, ⁵Duke University School of Medicine, Durham, NC, ⁶WEISS Memorial Hospital, Chicago, IL, ⁷Northwestern University, Chicago, IL, ⁸Vanderbilt University, Nashville, TN, ⁹University of Michigan, Ann Arbor, MI, ¹⁰Duke Univerisity, Durham, ¹¹University of Chicago, Chicago, IL, ¹²Choctaw Nation of Oklahoma Health Services Authority, McKinney, TX, ¹³Main Line Health, Wynnewood, PA, ¹⁴MedStar/Georgetown Washington Hospital Center, Silver Spring, MD, ¹⁵Duke University, Durham, NC, ¹⁶Massachusetts General Hospital, Boston, MA, ¹⁷Loyola University, Maywood, IL
Background/Purpose: theMednet.org is an online educational forum in which physicians submit clinical questions that are answered by experts in the field. RheumMadness is an online…
Abstract Number: 1572 • ACR Convergence 2024
Associations Between the Gut Microbiota, Ultra-Processed Food Intake, and Gastrointestinal Tract Symptoms in Patients with Systemic Sclerosis
Ju Young Lee¹, Swapna Joshi², Arissa Young³, Jen Labus², Zsuzsanna McMahan⁴, Ezinne Aja², Jonathan Jacobs² and Elizabeth Volkmann⁵, ¹David Geffen School of Medicine, UCLA, Los Angeles, CA, ²UCLA, Los Angeles, ³UCLA, Los Angeles, CA, ⁴UTHealth Houston Division of Rheumatology, Houston, TX, ⁵University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles
Background/Purpose: Alterations in the gastrointestinal (GI) microbiome (i.e., dysbiosis) are a feature of systemic sclerosis (SSc) [1]. Diet is a known modifier of the GI…
Abstract Number: 1521 • ACR Convergence 2024
Contemporary Lupus Nephritis Treatment and Outcomes Among Patients with Systemic Lupus Erythematosus in the United States
Aakash Patel¹, Baijun Zhou², Hyon K. Choi³ and April Jorge¹, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: Lupus nephritis (LN) is associated with excess morbidity and mortality, with prior studies finding a disproportionate impact on Black patients. We sought to determine…
Abstract Number: 1553 • ACR Convergence 2024
Safety, Pharmacokinetics, Clinical Efficacy and Exploratory Biomarker Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study of Enpatoran in Active Systemic and Cutaneous Lupus Erythematosus (SLE/CLE)
Torsten Witte¹, Ruth Fernandez Ruiz², Nadezda Abramova³, Dominika Weinelt³, Flavie Moreau⁴, Lena Klopp-Schulze⁵, Jamie Shaw⁶, Deborah Denis⁷ and Joerg Wenzel⁸, ¹Dept of Immunology and Rheumatology, Hannover, Germany, ²Global Clinical Development, EMD Serono, Billerica, MA, ³Global Patient Safety, the healthcare business of Merck KGaA, Darmstadt, Germany, ⁴Global Biostatistics, EMD Serono, Billerica, MA, ⁵Quantitative Pharmacology, the healthcare business of Merck KGaA, Darmstadt, Germany, ⁶Companion Diagnostics and Biomarker Strategy, EMD Serono, Billerica, MA, ⁷EMD Serono, Rockland, MA, ⁸Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany
Background/Purpose: Enpatoran, a highly selective, potent and reversible dual toll-like receptor 7/8 (TLR7/8) inhibitor, targets key innate and adaptive immune processes involved in the pathogenesis…
Abstract Number: 1568 • ACR Convergence 2024
Distribution of Proteinuria in Scleroderma Renal Crisis: A Multi-Center Study
Arifa Javed¹, Lilit Grigoryan², Alex Luta³, Sumbal Wajid², Lee Shapiro⁴, Virginia Steen⁵ and Swati Mehta⁶, ¹Albany Medical Center, Rensselaer, NY, ²Albany Medical Center, Albany, NY, ³MedStar Georgetown University Hospital, Rockville, MD, ⁴Albany Medical College, Stillwater, NY, ⁵Georgetown University School of Medicine, Washington, DC, ⁶Division of Nephrology, Department of Medicine, Albany Medical Center, Albany, NY
Background/Purpose: Scleroderma renal crisis (SRC) is a rare but life-threatening complication of systemic sclerosis (SSc), characterized by malignant hypertension and acute kidney injury (AKI). Proteinuria when present at the time of…
Abstract Number: 1532 • ACR Convergence 2024
Not yet on Track: Retrospective Chart Analysis Reveals Physician’s Treatment Approaches in SLE Fall Short of New EULAR Guidance
Maxine Yarnall¹, Ryan Rex² and Sawyer May¹, ¹Spherix Global Insights, Exton, PA, ²Spherix Global Insights, Chester Springs, PA
Background/Purpose: In October 2023, EULAR released updated recommendations for the management of SLE2. Notably, since the previous guidelines update in 2019, anifrolumab received approval for…
Abstract Number: 1437 • ACR Convergence 2024
Impact of Early Diagnosis in Patients with Axial Spondyloarthritis on Arterial Stiffness Progression
Sze-Lok Lau¹, Huan Meng², Isaac Cheng¹, Bryan PY Yan¹, Alex PW Lee¹, Ho So¹ and Lai-shan Tam³, ¹The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²The Faculty of Medicine, CUHK, Hong Kong, China (People's Republic), ³The Chinese University of Hong Kong, New Territories, Hong Kong
Background/Purpose: In patients with axial spondyloarthritis (AxSpA), we have reported that higher inflammatory burden as reflected by a longer disease duration, delay in diagnosis and…
Abstract Number: 1564 • ACR Convergence 2024
Incidence of Posttraumatic Stress Disorder Secondary to the Diagnosis of Systemic Sclerosis
Camille Zander¹, Sébastien De Almeida Chaves¹, Eva Bories², Martin MICHAUD Martin³, Grégoire Prevot¹, Antoine Yrondi¹ and Grégory Pugnet⁴, ¹CHU Toulouse, Toulouse, France, ²Clinique Monie, Toulouse, France, ³Clinique St Exupery, Toulouse, France, ⁴Toulouse Rangueil University Hospital, Toulouse, France
Background/Purpose: Systemic sclerosis (SSc) is a severe autoimmune connective-tissue disease characterized by vasculopathy, immune activation, and subsequent fibrosis of skin, lungs, heart, kidney or gastrointestinal…
Abstract Number: 1566 • ACR Convergence 2024
Comparative Analysis of Clinical Features and Outcomes in Late Onset vs. Early Onset Scleroderma Renal Crisis – A Multicenter Study
Sumbal Wajid¹, Lee Shapiro², Virginia Steen³, Robyn Domsic⁴, Paul J. Feustel⁵ and Swati Mehta⁶, ¹Albany Medical Center, Albany, NY, ²Division of Rheumatology, Department of Medicine, Albany Medical Center, Albany, NY, ³Georgetown University School of Medicine, Washington, DC, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁵Department of Neuroscience and Experimental Therapeutics, Albany Medical Center, Albany, NY, ⁶Division of Nephrology, Department of Medicine, Albany Medical Center, Albany, NY
Background/Purpose: Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis (SSc), historically described to occur within the first 5 years of SSc diagnosis.…
Abstract Number: 1534 • ACR Convergence 2024
Use and Safety of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients with Lupus Nephritis and Clinical Indications
April Jorge¹, Kila Panchot², Baijun Zhou², Aakash Patel¹ and Hyon K. Choi³, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have nephroprotective and cardioprotective benefits and may have a role in lupus nephritis (LN) treatment. 2023 EULAR SLE treatment guidelines…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].